Brilacidin PhaseII is active. Can it succeed where so many others have failed? 3in1 antiviral, anti-inflammatory, antibacterial. Extracellular, direct combat with SARs-Cov-2. Brilacidin brings a novel approach to the fight.

NIH-Sponsored ACTIV-3 Clinical Trial Closes Enrollment into Two Sub-Studies

https://www.nih.gov/news-events/news-releases...d%20(DSMB).